Spectral MD and the American College of Cardiology (ACC) announce a collaboration to investigate the clinical potential of Spectral MD’s DeepView technology in the assessment of critical limb ischemia (CLI).
CLI, an advanced form of peripheral artery disease, results from blockages in the lower extremity arteries. Early diagnosis is key to better outcomes, and if CLI is not diagnosed and treated quickly, it can lead to gangrene and even amputation.
Spectral MD is a wound healing prediction company that has developed proprietary optical technology and AI algorithms to accurately assess perfusion within the microvasculature of patients with peripheral artery disease. ACC has formed an advisory work group of experienced clinicians to provide scientific oversight and assessment of Spectral MD’s imaging technology to the identification of end-stage peripheral artery disease, a media release from Spectral MD notes.
“CLI is a severe condition and can be devastating for patients, but diagnostic evaluation is often inaccurate or invasive. This new, innovative technology has the potential to provide a more accurate assessment of tissue level perfusion in a less invasive way, leading to earlier diagnosis and hopefully improved outcomes and quality of life for CLI patients.”
— Dr Sahil A. Parikh, chair of the ACC member advisory work group
“This is an incredible opportunity to partner with such a highly-regarded and forward-thinking organization such as the ACC. We look forward to engaging the ACC’s physicians through a translational medicine approach to answer real-world clinical problems through the integration of our AI-enhanced imaging solution to guide therapies. Ultimately, we hope that this partnership results in the development of an imaging device that can improve the standard of care for patients suffering from peripheral artery disease.”
— Wensheng Fan, Chief Executive Officer and Co-Founder of Spectral MD
[Source(s): Spectral MD, PR Newswire]